Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout Feb 24, 2022 07:26AM
Needham & Company Reiterates Sage Therapeutics (SAGE) at Buy, but Expects Stock to be Down on Day 15 Endpoint Miss Feb 16, 2022 07:55AM
Bicycle Therapeutics Plc (BCYC), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE) - Needham's Favorite 2022 Biotech Picks Jan 19, 2022 07:14AM
Sage Therapeutics' (SAGE) CORAL Phase 3 Study Likely to Meet Primary Endpoint, But Not Enough to Drive Stock Higher - Needham & Company Jan 18, 2022 06:15AM
Sage Therapeutics (SAGE) PT Raised to $85 at Needham & Company; Named Neuroscience Top Pick for 2022 Jan 6, 2022 06:40AM


Oct 20, 2021 07:11AM Sage Therapeutics (SAGE) PT Lowered to $79 at Needham & Company
Sep 22, 2021 04:13PM Needham & Company Starts Sage Therapeutics (SAGE) at Buy, Adding to Conviction List
Dec 5, 2019 09:28AM Pre-Open Movers 12/05: (AUPH) (SEAC) (ACAD) Higher (SAGE) (HOME) (ESTC) Lower (more...)
Dec 7, 2017 04:05PM Sage Therapeutics (SAGE) PT Raised to $193 at Needham & Company
Nov 9, 2017 11:34AM Sage Therapeutics (SAGE) PT Raised to $100 at Needham & Company
Sep 13, 2017 07:52AM Sage Therapeutics (SAGE) PT Lowered to $86 at Needham & Company; 'Still Optimistic for Pipeline Despite Brexanolone Miss in High Risk SRSE Trial'
Aug 4, 2017 07:27AM Sage Therapeutics (SAGE) PT Raised to $95 at Needham & Company
Jun 13, 2017 08:03AM SAGE Therapeutics (SAGE): KOL Thoughts On SRSE - Needham
May 15, 2017 04:12PM Needham & Company Starts Sage Therapeutics (SAGE) at Buy
Jul 12, 2016 09:20AM Pre-Open Stock Movers 07/12: (SAGE) (STX) (RRD) Higher; (CYTR) (IMPV) (VRSN) Lower (more...)
May 15, 2015 11:23AM Notable Analyst Rating Changes 5/15: (UNP) (UPS) (JCP) Upgraded; (WYNN) (DE) (CLVS) Downgraded